An unmet need remains for effective, well-tolerated treatment options in advanced non-small-cell lung cancer that can alleviate the disease burden for a broad selection of patients. Nintedanib (Vargatef) is a potent, oral, triple angiokinase inhibitor of three distinct pro-angiogenic pathways. A recent Phase III trial of second-line nintedanib plus docetaxel met the primary end point of progression-free survival and demonstrated significant benefit in the key secondary end point of overall survival, with median overall survival greater than 1 year for patients with adenocarcinoma histology. This article summarizes preclinical and clinical experience with nintedanib in non-small-cell lung cancer to date and discusses how it may be used in the future, including prospects for individualizing treatment by tumor proliferation dynamics and molecular biomarkers of response.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1586/17512433.2014.945430 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Feasibility of detecting non-small cell lung cancer using exhaled breath condensate metabolomics.
J Breath Res
January 2025
School of Medicine and Pharmacy, Ocean University of China, 5 Yushan Rd, Qingdao, Shandong, 266003, CHINA.
Lung cancer is one of the most common malignancy in the world, and early detection of lung cancer remains a challenge. The exhaled breath condensate (EBC) from lung and trachea can be collected totally noninvasively. In this study, our aim is to identify differential metabolites between non-small cell lung cancer (NSCLC) and control EBC samples and discriminate NSCLC group from control group by orthogonal projections to latent structures-discriminant analysis (OPLS-DA) models.
View Article and Find Full Text PDFRNA analysis of patients with benign and malignant pulmonary nodules.
Oncol Lett
March 2025
Department of Hospital Quality and Control, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050001, P.R. China.
Pulmonary nodules are the main manifestations of early lung cancer. Non-small cell lung cancer is the most common histological type of lung cancer, and the main histological classification of non-small cell lung cancer is lung adenocarcinoma. The present study aimed to analyze the differentially expressed genes between patients with benign and malignant pulmonary nodules, and to identify potential therapeutic targets for lung adenocarcinoma.
View Article and Find Full Text PDFRisk factors for chronic postsurgical pain following thoracoscopic surgery for lung cancer.
Am J Transl Res
December 2024
Cardio-Thoracic Surgery, Jiangnan University Medical Center Wuxi 214000, Jiangsu, China.
Objective: Chronic post-surgical pain (CPSP) following thoracoscopic lung cancer surgery is a common and challenging complication. Identifying risk factors and predictive markers is essential for improving patient outcome.
Methods: In this retrospective case-control study, the clinical data from 106 patients with non-small cell lung cancer (NSCLC) who underwent thoracoscopic radical resection between January 2021 and December 2023 were comprehensively analyzed.
Exploring patient perspectives of barriers and facilitators to participating in hospital-based pulmonary rehabilitation in patients diagnosed with non-small-cell lung cancer treated with curative intent.
Ir J Med Sci
January 2025
Faculty of Education and Health Services, School of Medicine, University of Limerick, GarraunLimerick, V94 T9PX, Castletroy, Co, Ireland.
Background: Pulmonary rehabilitation (PR) is increasingly offered to patients who have undergone lung resection for non-small-cell lung carcinoma (NSCLC) as it can improve exercise tolerance and quality of life. However, designing and implementing such a complex multidisciplinary programme has its challenges.
Objective: This study aims to explore perspectives of patients offered PR services post-lung resection for NSCLC to gain an understanding of the potential barriers and facilitators behind implementing and designing PR programmes.
Cytokine release syndrome induced by dabrafenib and trametinib therapy in BRAF V600E-mutant non-small cell lung cancer.
Jpn J Clin Oncol
January 2025
Department of Respiratory Medicine and Allergology, Sapporo Medical University School of Medicine, South 1, West 17, Chuo-ku, Sapporo 060-8556, Japan.
Non-small cell lung cancer (NSCLC) with BRAF V600E mutations is responsive to targeted therapies, such as dabrafenib and trametinib. However, these treatments can lead to serious adverse events, including cytokine release syndrome (CRS). Herein, we report the case of a 75-year-old man with stage IVB NSCLC and a BRAF V600E mutation who developed severe CRS, manifesting hepatic and renal dysfunction, following treatment with dabrafenib and trametinib.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!